Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Insmed Appoints Myrtle Potter to its Board of Directors
Business Wire - Mon Dec 15, 7:01AM CST
Insmed Incorporated (Nasdaq:INSM) today announced the appointment of Myrtle Potter to its Board of Directors. Ms. Potter is currently CEO of Myrtle Potter & Company, a life sciences and healthcare advisory firm she founded in 2005. She was previously the President of Commercial Operations and Chief Operating Officer of Genentech and had extensive experience in senior operating roles at Bristol-Myers Squibb and Merck.
INSM: 15.29 (+0.15)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Insmed Provides End of Year Regulatory and Clinical Update
Business Wire - Mon Dec 15, 6:00AM CST
Insmed Incorporated (Nasdaq:INSM) today provides a regulatory and clinical update on the Company's development programs.
INSM: 15.29 (+0.15)
Critical Alerts For Twitter, Insmed, Spansion, Advanced Micro Devices and BlackBerry Released By InvestorsObserver
PR Newswire - Wed Dec 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TWTR, INSM, CODE, AMD and BBRY.
INSM: 15.29 (+0.15), AMD: 2.65 (-0.02), BBRY: 10.67 (-0.13), TWTR: 37.61 (+0.04), CODE: 34.55 (+0.64)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
INSM: 15.29 (+0.15), CY: 14.61 (+0.26), SSRI: 4.66 (+0.26), ORPN: 6.25 (-0.35), OTIC: 32.26 (+0.65), DMRC: 29.23 (+1.59), AVNR: 16.91 (+0.01), SSO.TO: 5.40 (+0.28), PAA.TO: 10.51 (+0.27), PAAS: 9.05 (+0.25), AMIC: 10.10 (+0.10), RGLD: 62.13 (+1.43), MTEX: 28.96 (unch), DGLY: 15.62 (+0.82)
Insmed to Participate at December Investment Conferences
Business Wire - Wed Nov 26, 7:30AM CST
Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in December:
INSM: 15.29 (+0.15)
Insmed Earnings Hindsight: Down 4.8% in Last 18 Days (INSM)
Comtex SmarTrend(R) - Mon Nov 24, 9:07AM CST
18 days ago, on November 6th, 2014, Insmed (NASDAQ:INSM) reported its earnings. Analysts, on average, expected a loss of $0.45 per share on sales of $0.0 thousand. Insmed actually reported a loss of $0.54 per share on sales of $0.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Since the company's report, shares of Insmed have fallen from $14.20 to $13.52, representing a loss of 4.8% in the past 18 days.
INSM: 15.29 (+0.15)
Update: Insmed Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Tue Nov 18, 7:50AM CST
INSM: 15.29 (+0.15)
Insmed Earnings Review: 11 Days after Announcement Shares Down 7.0% (INSM)
Comtex SmarTrend(R) - Mon Nov 17, 1:32PM CST
When Insmed (NASDAQ:INSM) reported earnings 11 days ago on November 6th, 2014, analysts, on average, expected the company to report a loss of $0.45 on sales of $0.0 thousand. The company actually reported a loss of $0.54 per share on sales of $0.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Shares of Insmed have slipped from $14.20 to $13.21, representing a loss of 7.0%, since the company reported earnings 11 days ago.
INSM: 15.29 (+0.15)
Global Retinopathy Of Prematurity Therapeutics Pipeline Review, H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdsmfd/retinopathy_of) has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Insmed Incorporated - Acucela Inc. - Gene Signal International SA - EyeGene, Inc. - Biomar Microbial Technologies Drug Profiles - mecasermin rinfabate - ranibizumab - aganirsen - Small Molecule for Retinopathy Of Prematurity - emixustat hydrochloride - EG-Mirotin - IB-09A0133 - R-200 For more information visit http://www.researchandmarkets.com/research/td...nopathy_of
INSM: 15.29 (+0.15)
Insmed's (INSM) CEO Bill Lewis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 1:39PM CST
INSM: 15.29 (+0.15)
Insmed posts 3Q loss
Automated Insights - Thu Nov 06, 9:06AM CST
BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Thursday reported a loss of $24 million, or 54 cents per share, in its third quarter.
INSM: 15.29 (+0.15)
Insmed (INSM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 7:25AM CST
INSM: 15.29 (+0.15)
Insmed misses by $0.08
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:53AM CST
INSM: 15.29 (+0.15)
Insmed Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 6:30AM CST
Insmed Incorporated (Nasdaq:INSM) today reported financial results for the three and nine months ended September 30, 2014.
INSM: 15.29 (+0.15)
Insmed to Host Third Quarter 2014 Financial Results Conference Call on Thursday, November 6, 2014
Business Wire - Fri Oct 31, 7:00AM CDT
Insmed Incorporated (Nasdaq: INSM), today announced that the Company will release financial results for the three month and nine months ended September 30, 2014, before the opening of the stock market on Thursday, November 6, 2014.
INSM: 15.29 (+0.15)
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 15.29 (+0.15), BCRX: 11.83 (+0.76), NBIX: 21.33 (+0.09), ONTY: 1.89 (+0.01), DYAX: 14.13 (+0.30)
Insmed to Participate in Leerink Partners' Rare Disease Roundtable
Business Wire - Wed Sep 24, 7:00AM CDT
Insmed Incorporated (Nasdaq:INSM), announces that Company management will participate in the upcoming Leerink Partners' Rare Disease Roundtable taking place October 1, 2014 at Le Parker Meridian Hotel in New York City. Will Lewis, Insmed's President and Chief Executive Officer, will participate in a fireside chat with Leerink Partners' analyst, Joseph P. Schwartz, at 2:20 p.m. Eastern time.
INSM: 15.29 (+0.15)
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma
PR Newswire - Thu Sep 11, 8:15AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.25, up 0.67%, with the index gaining 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), CytRx Corporation (NASDAQ: CYTR), Insmed Inc. (NASDAQ: INSM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research on these five companies can be accessed at:
DVAX: 15.35 (+0.30), INSM: 15.29 (+0.15), VRTX: 115.15 (+1.40), CYTR: 2.58 (+0.03), PRAN: 1.74 (-0.02)